Prof Judy de Haan is Head of the Cardiovascular Inflammation and Redox Biology Laboratory at the Baker Heart and Diabetes Institute in Melbourne, Australia. She is also Head of the Heart Failure Program at her institute. She holds adjunct Professorial appointments at Swinburne and La Trobe University in Melbourne, Australia. Prof de Haan is President of the Australian Atherosclerosis Society (2023–2025), President-Elect of the Society for Redox Research Australasia (2025–2026) and an appointed member of the Australian Cardiovascular Alliance (ACvA) Drug Discovery and Translation Flagship. With over 20 years of research in redox biology, Prof de Haan has developed innovative therapeutic strategies to protect against diabetic end-organ damage, particularly that seen in the eye, kidney and vasculature. This stems from her understanding of the oxidative and pro-inflammatory mechanisms that drive diabetic micro- and macrovascular complications. More recently, Prof de Haan has focused on the inflammatory role of the NLRP3-inflammasome/GasderminD axis and novel drug targets of this pathway to mitigate cardiovascular complications. Her research output includes 95+ publications (>6000 citations, H-index: 44) in top-ranked journals such as Circulation and Diabetes. Her work has been supported by competitive grants from the Australian government (NHMRC Ideas Grant), the Australian Heart Foundation, the Diabetes Australia Research Program, and the industry (Bayer, Reata Pharmaceuticals).